These 4 exercises can help you sleep better
If you struggle to get some shuteye, though, there are things you can do to help. While sleeping pills and cognitive behavioural therapy (CBT) are sometimes used to treat insomnia, they're not for everyone, and some sleeping pills may have side effects. That's why researchers have explored other, more accessible options people can try at home.
New analysis, published in the British Medical Journal, has focused on low-cost, low-risk, exercise-based treatments – from gentle movement to brisk walks – and found four types in particular may support better sleep.
These forms of activity aren't just widely available, they also slot easily into your everyday routine.
What did the study say?
Researchers compared 13 different ways of treating insomnia by reviewing data from 22 high-quality trials involving 1,348 participants. These included:
CBT
sleep hygiene advice – such as making sure your room is dark and cool and having a relaxing bedtime routine
acupuncture
exercise-based treatments
To compare outcomes, they analysed participants' sleep quality and also tracked things like improvements in total sleep time, number of nighttime wake-ups, and time taken to fall asleep.
The researchers say CBT "results in a large increase in total sleep time" based on sleep diary data, but these particular exercise-based interventions also performed surprisingly well.
The top 4 exercises for better sleep
Sleep benefits were measured differently across the top exercises, but all showed strong results in their own way. According to the findings, these were the standouts:
🧘 Yoga
Yoga showed some of the most impressive results across sleep categories.
Sleep time: Increased by nearly 2 hours
Sleep efficiency (time spent in bed asleep): Improved by 15%
Time spent awake during the night: Reduced by almost 1 hour
Sleep latency (time to fall asleep): Shortened by around 30 minutes
Researchers believe yoga's focus on mindfulness, breathing and body awareness could help reduce anxiety, which can be a major driver of sleep issues.
"Yoga may alter brain activity, thereby alleviating anxiety and depressive symptoms, which often interfere with a good night's sleep," the authors explained.
How to start: Look for beginner yoga videos online – many, including the hugely popular Yoga with Adrienne, are free of charge. You can also check if your local centre offers classes.
🥋 Tai Chi
This gentle, flowing martial art had one of the most consistent positive effects on sleep.
Sleep time: Increased by more than 50 minutes
Time spent awake during the night: Cut by over 30 minutes
Sleep latency (time to fall asleep): Reduced by 25 minutes
Sleep quality (time spent asleep while in bed): Showed improvements lasting up to 2 years
According to the study, Tai Chi's emphasis on breath control and relaxation may dampen nervous system activity, lowering hyperarousal (the feeling of being on edge) and anxiety, all of which can interfere with a good night's sleep.
"It's combination of meditative movement and mindfulness may promote emotional regulation and reduce anxiety," the researchers said.
How to start: As well as being offered by some community centres and leisure centres, some local Age UKs offer accessible Tai Chi classes, particularly for older adults.
🚶 Walking or jogging
Prefer being out in the fresh air? Walking or jogging came out as another top exercise option for easing insomnia symptoms.
While the study didn't break down results for sleep time or efficiency like it did for yoga or Tai Chi, participants' Insomnia Severity Score was reduced by 10 points.
Researchers suggest this could be down to aerobic activity boosting melatonin – a hormone that regulates the wake-sleep cycle – and helping you feel more physically tired, making falling (and staying) asleep easier.
How to start: Try starting with a brisk walk and interspersing short intervals of faster walking or jogging. If you want to build up the distance, the free NHS Couch to 5k programme could see you hitting just over three miles in as little as nine weeks.
Why exercise might work for sleep
While each activity works slightly differently, they all seem to promote more restful sleep by:
Regulating stress and anxiety
Increasing physical fatigue (which promotes better rest)
Boosting melatonin (the sleep hormone)
Supporting emotional resilience and reducing mental "chatter"
Keep in mind it's best to avoid intense workouts right before bed – they can leave you feeling too wired. Morning or early evening sessions are usually best if you're aiming for a better night's sleep.
If you're still struggling with sleep despite trying these techniques, speak to your GP for advice.
Read more about sleep:
Ever fallen asleep in public like Hugh Grant at Wimbledon? This is what it could mean (Yahoo Life UK, 4-min read)
From ageing faster to early death, how nightmares really affect you according to a dream expert (Yahoo Life UK, 7-min read)
People are using antihistamines for PMDD and insomnia, but do they work? (Yahoo Life UK, 5-min read)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
20 minutes ago
- Medscape
Social Media Reveals IBS Woes Missed by Clinics
TOPLINE: An analysis of irritable bowel syndrome (IBS)-related posts on X reveals discussions spanning symptoms, dietary triggers, peer support, and mental health — suggesting that traditional healthcare settings may not fully meet patients' needs and underscoring the value of integrating social media insights into IBS care models. METHODOLOGY: Social media platforms like X are frequentlly used to share health experiences and provide patient-generated insights. Researchers analyzed 12,345 IBS-related posts on X (April 2006-August 2024), using search terms capable of capturing user experiences and concerns. The dataset was processed to retain relevant information from texts and emojis. Posts with fewer than three words were removed. Sentiment analysis (score range, -1 to +1) was applied to 8864 posts, which were classified as positive, neutral, or negative. Topic modeling was applied to 2532 posts with ≥ 50 words to identify core subjects and themes. TAKEAWAY: Sentiment was primarily neutral (45.9%), followed by positive (35.4%) and negative (18.7%), suggesting that users often shared advice or information rather than strong emotions. Sentiment remained relatively consistent over time, with fluctuations linked to major IBS-related milestones (eg, new diagnostic criteria, high-profile publications, awareness campaigns). Main post themes included physical symptoms (15.6%), diet/triggers (15.1%), social support (14.2%), comorbidities (12.2%), research and treatment (12.2%), quality of life (12.0%), awareness (11.5%), and mental health (7.2%). Posts on physical symptoms had the highest proportion of negative sentiment (32.4%), whereas social support post were the most positive (53.7%). Mental health and research/treatment posts were mostly neutral due to their educational or informational nature. Post contributors included self-identified IBS patients (61.3%), healthcare professionals (12.8%), organizations/advocacy groups (10.5%), and general commenters (15.4%). IN PRACTICE: 'Patients turn to social media primarily because of unmet informational needs regarding day-to-day symptom management (evidenced by the prevalence of dietary and trigger discussions) and desires for experiential validation that clinical encounters may not provide (demonstrated by the high engagement with personal narrative content),' the authors wrote. SOURCE: This study was led by Ravi Shankar and Alexander Wenjun Yip, Alexandra Hospital in Singapore. It was published online in Scientific Reports. LIMITATIONS: Data were limited to X and may not reflect the entire spectrum of online IBS discussions. Users not active in online discussions — especially older adults or those with limited digital literacy/access — may have been underrepresented. DISCLOSURES: This study did not receive any specific grant funding. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
an hour ago
- Yahoo
INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface
Graphene-based BCI demonstrates high-resolution brain decoding and mapping in patients undergoing tumor resection at the Manchester Centre for Clinical Neurosciences Initial four patient cohort has shown no safety concerns to date that would prevent the completion of this first-in-human study. BARCELONA, Spain, July 29, 2025--(BUSINESS WIRE)--INBRAIN Neuroelectronics today announced the interim analysis of findings from the world's first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for resection of brain tumors. The primary objective of the study (NCT06368310) is to assess the safety of INBRAIN's brain-computer interface (BCI) during brain tumor surgery. Secondary objectives include evaluating the quality of neural signals captured by the device, its ability to deliver targeted brain stimulation, the consistency of its performance throughout the procedure, and its overall suitability for use in the neurosurgical operating room. A total of 8 to 10 patients are expected to be enrolled to validate the safety and functional performance of the graphene-based BCI. The study design included an interim analysis after the first four patients had been recruited to ensure patient safety and data quality. Interim analysis of the results from the first cohort of four patients enrolled in the study demonstrated no device-related adverse events, a key component of the primary endpoint of the study. During awake language mapping, the device captured distinct high gamma activity linked to different phonemes, the smallest units of sound in speech, showcasing exceptional spatial and temporal resolution, even with micrometer-scale contacts. The ultra-thin, sub-micrometer graphene electrodes also proved compatible with commercially available, CE-marked electrophysiology systems, reliably recording real-time brain signals throughout the surgical procedures. "The ability to detect high-frequency neural activity with micrometer-scale precision opens new possibilities for understanding brain-tumor interactions and broader brain function in neuro-related disorders," said Mr. David Coope, Chief Investigator and Consultant Neurosurgeon at the Manchester Centre for Clinical Neurosciences, the Geoffrey Jefferson Brain Research Centre and the University of Manchester. "This technology could be transformative, not only for improving surgical outcomes but for unlocking new treatment pathways." Throughout the procedures, INBRAIN's BCI enabled high-resolution brain signal monitoring, addressing one of the most pressing challenges in neurosurgery: achieving precise tumor removal while preserving essential functions such as speech, movement, and cognition. The device was used in parallel with standard clinical monitoring tools, maintaining consistent performance across the surgical window. "This milestone demonstrates that graphene-based brain-computer interfaces can be deployed in the operating room and deliver a level of neural fidelity not achievable with traditional materials," said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. "We're moving toward a future where neurosurgeons and neurologists can rely on real-time, high-definition brain data to guide personalized interventions." INBRAIN's platform is powered by ultra-flexible, thin-film graphene semiconductors that conform more precisely to the brain surface than conventional strip electrodes. The BCI features high-density, multiscale, bidirectional contacts for superior decoding and modulation, and reduced graphene oxide (rGO) nanoporous matrices that enhance sensitivity and signal resolution. In preclinical studies, the GCI significantly outperformed platinum-based electrodes in detecting high gamma frequencies (80–130 Hz) critical for speech decoding, with statistical significance (p < 0.01). Clinical Advantages Graphene technology offers several benefits for neurosurgical procedures. It enhances surgical precision by enabling smaller and more densely packed electrodes, allowing surgeons to define and preserve critical functional areas during tumor resection. Its flexibility enables accurate decoding and mapping in anatomically complex or hard-to-access brain regions, including the walls of the tumor resection cavity. Additionally, the device's ability to decode high-frequency activity offers huge scientific opportunities including the potential to reveal in situ interactions between glioma cells and neurons, offering potential insights into new therapeutic targets for halting tumor progression. "We're not delivering incremental innovation, we're enabling entirely new capabilities," said Kostas Kostarelos, Co-Founder of INBRAIN and Chief Scientific Investigator of the study and Professor of Nanomedicine at the University of Manchester, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, and Programme Lead for the Next Generation Therapeutics Theme of the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC). "This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology." As the first safety study of a graphene-based neural interface in humans, this study marks a foundational step toward the development of BCI therapeutic systems for chronic neurological diseases, pioneering a new era of real-time, precision neurology. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit and follow us on LinkedIn. About Northern Care Alliance (NCA) Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives. More information about the NCA can be found at About the National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. About the NIHR Manchester Biomedical Research Centre (BRC) The NIHR Manchester Biomedical Research Centre (BRC) transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Manchester BRC is hosted by Manchester University NHS Foundation Trust and The University of Manchester – in partnership with five NHS trusts; Blackpool Teaching Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and the Northern Care Alliance NHS Foundation Trust. About The University of Manchester The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 38th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries. Together, they are tackling the world's biggest challenges – the University's social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government's Research Excellence Framework (REF) 2021. The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK's leading employers (The Graduate Market, 2023). View source version on Contacts Media Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Binding term sheet signed; transaction subject to customary conditions and approvals Closing expected in Q4 2025 GENEVA, SWITZERLAND / / July 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ("Relief" or the "Company"), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the execution of a binding term sheet for a proposed business combination with NeuroX Group SA ("NeuroX"), a privately held company that recently acquired the assets and operations of MindMaze - a recognized leader in digital neurotherapeutics and brain health technologies. The envisaged combination aims to create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform to improve the quality of life of patients, caregivers and families. NeuroX will contribute a clinically validated, risk-mitigated portfolio supported by multiple milestones achieved across technological development, regulatory approvals, and market access, as well as a solid network of pharmaceutical partners. Dr. Raghuram Selvaraju, chairman of the board of directors of Relief, commented: "By entering into this transaction, we intend to bring a global pioneer in digital neurotherapeutics to the public markets through the Relief ecosystem. NeuroX, which now operates the MindMaze platform, has a compelling business model, an established track record of innovation, and a distinctive technology that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. We believe this combination has the potential to create significant value for patients, clinicians, and shareholders. Importantly, it offers existing Relief shareholders the opportunity to participate in the growth of a scalable enterprise with potential to become a multi-billion-dollar company." Alexandre Capet, head of corporate development of NeuroX, commented: "The business combination with Relief presents a timely opportunity to build on the vision and ambition set by MindMaze on a global scale, accelerating our market presence and next phase of growth. Over the past decade, we have built a robust portfolio of clinically validated digital neurotherapeutics and invested heavily in commercial infrastructure, AI technology, and R&D. With increased visibility and a solid foundation in place, we believe this transaction comes at a pivotal inflection point in our journey. It positions us to scale more effectively as a publicly listed company and expand the reach of our breakthrough therapies." NeuroX and MindMaze OverviewNeuroX is a Swiss-based, commercial-stage company. In 2025, NeuroX acquired the operations and intellectual property of the legacy MindMaze group ("MindMaze"), including the MindMaze ® brand. MindMaze has developed first-of-its-kind neurotherapeutics that provide disease-modifying motor and cognitive treatments for neurological diseases and brain disorders. These neurotherapeutics are delivered through proprietary software and hardware, underpinned by an advanced brain technology platform that integrates wearables and sensors, and provides digital assessments as well as telehealth services. The unique suite of MindMaze solutions is delivered globally across the continuum-of-care, both in-clinic and in patients' home, to successfully address some of neurology's major unmet needs. NeuroX has already partnered with leading pharmaceutical companies that use its proprietary technology across multiple clinical trials. Over the last decade, MindMaze has invested more than USD 350 million to establish clinical evidence, demonstrate significant medico-economic outcomes, and market MindMaze's disease-modifying therapeutic platform across neurological diseases, including stroke, Parkinson's disease, and at-risk aging. In the United States, MindMaze has received a unique reimbursement code (CAT-3) to support the delivery of its home-based neurotherapeutic training. Its R&D pipeline focuses on adjacent neurological diseases, such as spinal cord injury, multiple sclerosis, traumatic brain injury, and Alzheimer's disease/dementia. Moved by the mission to accelerate the brain's ability to recover, the MindMaze platform innovates by combining software-delivered behavioral treatments, drugs, devices, data, and AI to establish a new paradigm of precision medicine in neurology and neural repair. For more information, visit . Transaction OverviewUnder the terms of the term sheet, NeuroX shareholders will exchange at closing all outstanding shares of NeuroX for newly issued shares of Relief. The transaction is based on agreed equity valuations of CHF 100 million for Relief, representing a significant premium to its current market capitalization, and CHF 1 billion for NeuroX. Post-closing, Relief shareholders are expected to own approximately 9% of the combined entity on a fully diluted basis, with NeuroX shareholders holding the remaining 91%. The combined entity's shares will continue trading on the SIX Swiss Exchange. The term sheet provides for full exclusivity during the negotiation and finalization of a definitive agreement, as well as a customary break fee, reflecting the commitment of both parties to advance the transaction. It also includes a one-year post-closing reset mechanism to adjust the ownership ratio within certain parameters based on the combined entity's market value at that time. The transaction remains subject, among other customary conditions, to the negotiation and execution of a definitive agreement, completion of satisfactory due diligence, approval by the shareholders of both companies, completion of concurrent financing by NeuroX, filing of regulatory documentation with the applicable securities authorities, and receipt of regulatory and stock exchange approvals. There can be no assurance that the transaction will be completed on the terms described herein or at all. The parties expect to finalize the definitive transaction agreement in Q3 2025, with closing anticipated in Q4 2025. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. The Company has access to a CHF 50 million equity commitment in the form of a share subscription facility with its largest shareholder, Global Emerging Markets (GEM). For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information provided on NeuroX and MindMaze within this press release is provided by NeuroX. Relief makes no representation or warranty as to the accuracy, completeness, or reliability of such information and disclaims any obligation or liability in connection with it. No offer or solicitation: This press release does not constitute (i) a prospectus within the meaning of the Swiss Financial Services Act or under any other applicable laws, (ii) a solicitation of proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (iii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Relief, NeuroX, or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the laws of such other jurisdiction. This press release should not be treated as offering material of any sort and is for information purposes only. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data